These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27845108)

  • 1. Re: Lethal Prostate Cancer in the PLCO Cancer Screening Trial.
    Taneja SS
    J Urol; 2016 Dec; 196(6):1677. PubMed ID: 27845108
    [No Abstract]   [Full Text] [Related]  

  • 2. Insights from the PLCO trial about prostate cancer screening.
    Gulati R; Albertsen PC
    Cancer; 2017 Feb; 123(4):546-548. PubMed ID: 27906455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for cancer: lessons learned from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Grubb RL; Pinsky P; Prorok PC; Andriole GL
    Eur Urol; 2015 Oct; 68(4):545-6. PubMed ID: 25959167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A different interpretation of the efficacy of lung cancer screening in the PLCO trial.
    Sagawa M; Nakayama T; Sobue T;
    Eur J Epidemiol; 2016 Feb; 31(2):211-2. PubMed ID: 26197850
    [No Abstract]   [Full Text] [Related]  

  • 7. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial.
    Lotan Y; Karam JA; Shariat SF; Gupta A; Roupret M; Bensalah K; Margulis V
    Urol Oncol; 2016 Apr; 34(4):167.e9-16. PubMed ID: 26602092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Andriole GL
    Recent Results Cancer Res; 2014; 202():53-7. PubMed ID: 24531777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lethal Prostate Cancer in the PLCO Cancer Screening Trial.
    Shoag J; Mittal S; Halpern JA; Scherr D; Hu JC; Barbieri CE
    Eur Urol; 2016 Jul; 70(1):2-5. PubMed ID: 27166670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall mortality in men and women in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Pinsky PF; Miller EA; Zhu CS; Prorok PC
    J Med Screen; 2019 Sep; 26(3):127-134. PubMed ID: 30943843
    [No Abstract]   [Full Text] [Related]  

  • 11. Focused Decision Support: a Data Mining Tool to Query the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Dataset and Guide Screening Management for the Individual Patient.
    Sharma A; Hostetter J; Morrison J; Wang K; Siegel E
    J Digit Imaging; 2016 Apr; 29(2):160-4. PubMed ID: 26385814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF; Andriole GL; Kramer BS; Hayes RB; Prorok PC; Gohagan JK;
    J Urol; 2005 Mar; 173(3):746-50; discussion 750-1. PubMed ID: 15711261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for prostate cancer: reflecting on the quality of evidence from the ERSPC and PLCO studies.
    Ilic D
    Recent Results Cancer Res; 2014; 202():65-71. PubMed ID: 24531779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Quality Management (CQM) in the PLCO Trial.
    Gohagan JK; O'Brien B; Hasson MA; Umbel KD; Bridgeman B; Kramer BS; Reding D; Gren L; Wright P; Riley T; Prorok PC
    Rev Recent Clin Trials; 2015; 10(3):223-32. PubMed ID: 26238118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-compliance with the initial screening exam visit in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    Marcus PM; Ogden SL; Gren LH; Childs JC; Pretzel SM; Lamerato LE; Walsh K; Rozjabek HM; Mabie J; Thomas B; Riley T
    Prev Med; 2014 Oct; 67():82-8. PubMed ID: 25038532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource.
    Zhu CS; Pinsky PF; Kramer BS; Prorok PC; Purdue MP; Berg CD; Gohagan JK
    J Natl Cancer Inst; 2013 Nov; 105(22):1684-93. PubMed ID: 24115361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coordination and management of a large multicenter screening trial: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    O'Brien B; Nichaman L; Browne JE; Levin DL; Prorok PC; Gohagan JK;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):310S-328S. PubMed ID: 11189685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Re-evaluating PSA Testing Rates in the PLCO Trial.
    Roobol MJ
    Eur Urol; 2016 Oct; 70(4):700-701. PubMed ID: 27495847
    [No Abstract]   [Full Text] [Related]  

  • 19. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Pinsky PF; Miller A; Kramer BS; Church T; Reding D; Prorok P; Gelmann E; Schoen RE; Buys S; Hayes RB; Berg CD
    Am J Epidemiol; 2007 Apr; 165(8):874-81. PubMed ID: 17244633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERSPC, PLCO studies and critique of cochrane review 2013.
    Schröder FH
    Recent Results Cancer Res; 2014; 202():59-63. PubMed ID: 24531778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.